Streetbeat News

Analyst Ratings

COHU

Needham analyst Quinn Bolton has maintained a 'Buy' rating on Cohu (NASDAQ:COHU) but lowered the price target from $52 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:32 am

BTCUSD

ETHUSD

SOLUSD

TIAUSD

Ex-Ark Invest analyst, Chris Burniske, predicts that the current bull run in the crypto market may lose momentum soon. He classifies key cryptos into two categories: Bitcoin (BTC) and Ethereum (ETH) as the original crypto barbell, and Solana (SOL) and Tiamonds (TIA) as the next-gen blockchain platforms. Despite the bullish sentiment, the market shows volatility and traders remain wary.

Portfolio Pulse from Benzinga Neuro

November 03, 2023 | 11:28 am

RCM

Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on R1 RCM (NASDAQ:RCM) but lowered the price target from $20 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:28 am

PCTY

Needham analyst Scott Berg has maintained a 'Buy' rating on Paylocity Holding (NASDAQ:PCTY), but lowered the price target from $325 to $200.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:27 am

PZZA

Keybanc analyst Eric Gonzalez has maintained an Overweight rating on Papa John's International (NASDAQ:PZZA) but lowered the price target from $90 to $75.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:26 am

BILL

Needham analyst Scott Berg has maintained a 'Buy' rating on BILL Holdings (NYSE:BILL) but lowered the price target from $200 to $100.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:25 am

VIR

Needham analyst Joseph Stringer has maintained a 'Buy' rating on Vir Biotechnology (NASDAQ:VIR), but lowered the price target from $22 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:22 am

PCTY

Keybanc analyst Jason Celino maintains an Overweight rating on Paylocity Holding (NASDAQ:PCTY) but lowers the price target from $255 to $197.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:20 am

ITCI

Needham analyst Ami Fadia maintains a 'Buy' rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $71 to $72.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:19 am

MCHP

Keybanc analyst Weston Twigg has maintained an Overweight rating on Microchip Technology (NASDAQ:MCHP) but lowered the price target from $95 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 11:18 am